

Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results from a Randomized Trial
In this medfyle
Improved 15-year OS in early breast cancer with adjuvant capecitabine.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in the Journal of Clinical Oncology® (JCO), an American Society of Clinical Oncology Journal, through an official agreement with Wolters Kluwer.
The summary content was prepared by Louise Gardner for Medfyle, reviewed & approved by Prof Valentina Guarneri, MD, PhD.
Original article:
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, Tanner M, Ahlgren J, Auvinen P, Lahdenperä O, Villman K, Nyandoto P, Nilsson G, Poikonen-Saksela P, Kataja V, Bono P, Junnila J, Lindman H. Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. J Clin Oncol. 2022 Apr 1;40(10):1051-1058. doi: 10.1200/JCO.21.02054. Epub 2022 Jan 12. PMID: 35020465; PMCID: PMC8966968.
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of the American Society of Clinical Oncology.